Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …

Insulin-dependent diabetes may occur in patients with cancers who are treated with
checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two …

Abstract Context Pembrolizumab (Keytruda; Merck Sharp & Dohme) is a humanized IgG4
monoclonal antibody used in cancer immunotherapy. It targets the programmed cell death-1 …

Objective To better define the rare adverse event (AE) of diabetes mellitus associated with
immune checkpoint inhibitors (ICIs). Design and methods We report the case of a lung …

Background Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat
patients with many advanced solid tumor and hematological malignancies to improve their …

Non-recirculating tissue-resident memory T cells (TRMs) are the predominant T cell subset
in diverse tissue sites, where they mediate protective immune responses in situ. Here, we …

Anticancer immunotherapy, in the form of immune checkpoint inhibition, is a paradigm shift
that has transformed the care of patients with different types of solid and hematologic …

Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer
immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies …

Neutrophils have both antimicrobial ability and pathogenic effect in the immune system,
neutrophil extracellular traps (NETs) formation is one of the representative behaviors of their …

Pembrolizumab is an anti-cancer drug that targets programmed cell death protein-1 (PD-1)
receptors on lymphocytes resulting in their activation against tumour cells. PD-1 receptors …